EA201890428A1 - Ингибиторы контрольных точек иммунного ответа для применения в лечении различных видов рака крови - Google Patents
Ингибиторы контрольных точек иммунного ответа для применения в лечении различных видов рака кровиInfo
- Publication number
- EA201890428A1 EA201890428A1 EA201890428A EA201890428A EA201890428A1 EA 201890428 A1 EA201890428 A1 EA 201890428A1 EA 201890428 A EA201890428 A EA 201890428A EA 201890428 A EA201890428 A EA 201890428A EA 201890428 A1 EA201890428 A1 EA 201890428A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cancer
- inhibitors
- blood
- treatment
- application
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000008280 blood Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
- 102100035488 Nectin-2 Human genes 0.000 abstract 7
- 102100031351 Galectin-9 Human genes 0.000 abstract 3
- 101710121810 Galectin-9 Proteins 0.000 abstract 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 abstract 3
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 abstract 3
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 abstract 3
- 101150065403 NECTIN2 gene Proteins 0.000 abstract 3
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 abstract 3
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 abstract 3
- 108060005251 Nectin Proteins 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 201000005787 hematologic cancer Diseases 0.000 abstract 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
В настоящем изобретении предложен ингибитор против CD112 (нектин-2, PVRL2), CD155 (PVR), галектин-9, TIM-3 и/или TIGIT для применения в способе лечения рака крови, в частности острого миелоидного лейкоза (ОМЛ). Кроме того, в настоящем изобретении предложена фармацевтическая композиция, содержащая ингибитор против CD112 (нектин-2, PVRL2), CD155 (PVR), галектина-9, TIM-3 и/или TIGIT и CAR T-клетку. В настоящем изобретении дополнительно предложена фармацевтическая композиция, содержащая ингибитор против CD112 (нектин-2, PVRL2), CD155(PVR), галектина-9, TIM-3 и/или TIGIT и конструкцию антитела, способную к привлечению T-клеток.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562201461P | 2015-08-05 | 2015-08-05 | |
PCT/EP2016/068726 WO2017021526A1 (en) | 2015-08-05 | 2016-08-05 | Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201890428A1 true EA201890428A1 (ru) | 2018-07-31 |
EA039307B1 EA039307B1 (ru) | 2022-01-12 |
Family
ID=56801503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201890428A EA039307B1 (ru) | 2015-08-05 | 2016-08-05 | Применение фармацевтической композиции, содержащей ингибиторы контрольных точек иммунного ответа, для лечения острого миелоидного лейкоза |
Country Status (23)
Country | Link |
---|---|
US (2) | US20170037133A1 (ru) |
EP (1) | EP3331915B1 (ru) |
JP (1) | JP7170532B2 (ru) |
CN (1) | CN108473572B (ru) |
AU (1) | AU2016301961B2 (ru) |
CA (1) | CA2996015A1 (ru) |
DK (1) | DK3331915T3 (ru) |
EA (1) | EA039307B1 (ru) |
ES (1) | ES2861436T3 (ru) |
HK (1) | HK1249524A1 (ru) |
HU (1) | HUE053763T2 (ru) |
IL (1) | IL256874B (ru) |
JO (1) | JO3620B1 (ru) |
LT (1) | LT3331915T (ru) |
MX (1) | MX2018001351A (ru) |
MY (1) | MY186582A (ru) |
PH (1) | PH12018500120A1 (ru) |
SG (1) | SG10202000914VA (ru) |
SI (1) | SI3331915T1 (ru) |
TW (1) | TWI719041B (ru) |
UA (1) | UA125375C2 (ru) |
WO (1) | WO2017021526A1 (ru) |
ZA (1) | ZA201708598B (ru) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3978929A1 (en) | 2015-02-19 | 2022-04-06 | Compugen Ltd. | Pvrig polypeptides and methods of treatment |
EP3295951B1 (en) | 2015-02-19 | 2020-04-22 | Compugen Ltd. | Anti-pvrig antibodies and methods of use |
US11827904B2 (en) | 2015-04-29 | 2023-11-28 | Fred Hutchinson Cancer Center | Modified stem cells and uses thereof |
TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit結合劑和彼之用途 |
WO2017004079A1 (en) | 2015-06-29 | 2017-01-05 | Biomed Valley Discoveries, Inc. | Lpt-723 and immune checkpoint inhibitor combinations and methods of treatment |
US11098130B1 (en) | 2015-08-03 | 2021-08-24 | Tasrif Pharmaceutical, LLC | Antibodies and antibody fragments against the CD155 receptor and methods of use thereof |
BR112018067522A2 (pt) | 2016-03-01 | 2019-02-05 | Univ Of Rijeka Faculty Of Medicine | anticorpos específicos para receptor de poliovírus humano (pvr) |
SG11201810023QA (en) | 2016-05-27 | 2018-12-28 | Agenus Inc | Anti-tim-3 antibodies and methods of use thereof |
AU2017297506A1 (en) | 2016-07-14 | 2019-02-21 | Bristol-Myers Squibb Company | Antibodies against TIM3 and uses thereof |
DK3347379T5 (da) | 2016-08-17 | 2020-06-15 | Compugen Ltd | Anti-tigit-antistoffer, anti-pvrig-antistoffer og kombinationer deraf |
EA201990591A1 (ru) | 2016-09-23 | 2019-08-30 | Фред Хатчинсон Кэнсер Рисерч Сентер | Tcr, специфичные к минорному антигену гистосовместимости (h) ha-1, и их применения |
MX2019006072A (es) | 2016-11-30 | 2019-08-14 | Oncomed Pharm Inc | Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit). |
BR112019018863A8 (pt) | 2017-03-15 | 2023-05-02 | Hutchinson Fred Cancer Res | Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos |
EP3618863B1 (en) | 2017-05-01 | 2023-07-26 | Agenus Inc. | Anti-tigit antibodies and methods of use thereof |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
KR102641269B1 (ko) | 2017-05-24 | 2024-02-26 | 이펙터 테라퓨틱스, 인크. | 개선된 항종양 면역 반응을 위한 조성물 및 방법 |
WO2018220446A1 (en) | 2017-06-01 | 2018-12-06 | Compugen Ltd. | Triple combination antibody therapies |
WO2018229163A1 (en) * | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
EP3484925B1 (en) | 2017-07-27 | 2020-05-27 | iTeos Therapeutics SA | Anti-tigit antibodies |
US20210106618A1 (en) | 2017-09-06 | 2021-04-15 | Fred Hutchinson Cancer Research Center | Methods for improving adoptive cell therapy |
CA3071661A1 (en) | 2017-09-06 | 2019-03-14 | Fred Hutchinson Cancer Research Center | Strep-tag specific chimeric receptors and uses thereof |
EP3678689A1 (en) | 2017-09-06 | 2020-07-15 | Fred Hutchinson Cancer Research Center | Strep-tag specific binding proteins and uses thereof |
WO2019079777A1 (en) | 2017-10-20 | 2019-04-25 | Fred Hutchinson Cancer Research Center | COMPOSITIONS AND METHODS FOR TIGIT AND / OR CD112R TARGETING IMMUNOTHERAPY OR COMPRISING THE OVEREXPRESSION OF CD226 |
WO2019102456A1 (en) | 2017-11-27 | 2019-05-31 | University Of Rijeka Faculty Of Medicine | Immunotoxins for treating cancer |
WO2019109047A1 (en) | 2017-12-01 | 2019-06-06 | Fred Hutchinson Cancer Research Center | Binding proteins specific for 5t4 and uses thereof |
WO2019140278A1 (en) | 2018-01-11 | 2019-07-18 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting core binding factor antigens |
MX2020008795A (es) * | 2018-02-28 | 2020-10-08 | Yuhan Corp | Anti cuerpos anti tigit y usos de los mismos. |
JP2021518104A (ja) * | 2018-03-14 | 2021-08-02 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 操作された細胞、t細胞免疫調節抗体、およびそれらの使用方法 |
SG11202010025YA (en) | 2018-05-31 | 2020-11-27 | Glyconex Inc | Therapeutic antibodies binding to biantennary lewis b and lewis y antigens |
WO2020018964A1 (en) | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
MX2021001938A (es) | 2018-08-22 | 2021-04-19 | Fred Hutchinson Cancer Center | Inmunoterapia dirigida a antigenos kras o her2. |
CA3107596A1 (en) | 2018-08-23 | 2020-02-27 | Seagen Inc. | Anti-tigit antibodies |
CN110511912B (zh) * | 2018-08-30 | 2024-03-22 | 浙江煦顼技术有限公司 | 免疫细胞的功能调节 |
WO2020068702A1 (en) | 2018-09-24 | 2020-04-02 | Fred Hutchinson Cancer Research Center | Chimeric receptor proteins and uses thereof |
JP2022506781A (ja) | 2018-11-09 | 2022-01-17 | フレッド ハッチンソン キャンサー リサーチ センター | メソテリンを標的とする免疫療法 |
LT3898668T (lt) | 2018-12-19 | 2023-11-10 | Humabs Biomed Sa | Antikūnai, neutralizuojantys hepatito b virusą ir jų panaudojimas |
WO2020144697A1 (en) * | 2019-01-13 | 2020-07-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human nectin-2 |
CA3130618A1 (en) | 2019-02-20 | 2020-08-27 | Fred Hutchinson Cancer Research Center | Binding proteins specific for ras neoantigens and uses thereof |
CA3132845A1 (en) | 2019-03-11 | 2020-09-17 | Fred Hutchinson Cancer Research Center | High avidity wt1 t cell receptors and uses thereof |
US20220242955A1 (en) * | 2019-07-11 | 2022-08-04 | Dana-Farber Cancer Institute, Inc. | Targeting galectin-9 as a therapeutic strategy for t-cell exhaustion in t-cell acute lymphoblastic leukemia |
EP4017872A1 (en) | 2019-08-20 | 2022-06-29 | Fred Hutchinson Cancer Center | T-cell immunotherapy specific for wt-1 |
MX2022002231A (es) | 2019-08-29 | 2022-03-22 | Vir Biotechnology Inc | Composiciones de anticuerpos y metodos para tratar la infeccion por el virus de la hepatitis b. |
EP3789485A1 (en) * | 2019-09-06 | 2021-03-10 | ONK Therapeutics Limited | Cellular therapies for cancer |
US20230057899A1 (en) | 2019-12-05 | 2023-02-23 | Compugen Ltd. | Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing |
WO2021257124A1 (en) | 2020-06-18 | 2021-12-23 | Genentech, Inc. | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
KR20230042023A (ko) | 2020-06-24 | 2023-03-27 | 비르 바이오테크놀로지, 인코포레이티드 | 조작된 b형 간염 바이러스 중화 항체 및 이의 용도 |
TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Tigit及cd112r阻斷 |
CN114163532A (zh) * | 2020-09-10 | 2022-03-11 | 南京北恒生物科技有限公司 | 包含新型共刺激结构域的嵌合抗原受体及其用途 |
WO2022066973A1 (en) | 2020-09-24 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting pbk or oip5 antigens |
CN116724053A (zh) | 2020-09-24 | 2023-09-08 | 弗雷德哈钦森癌症中心 | 靶向sox2抗原的免疫治疗 |
TW202222841A (zh) | 2020-10-06 | 2022-06-16 | 福瑞德哈金森腫瘤研究中心 | 用於治療表現mage-a1之疾病的組成物及方法 |
CN112480264B (zh) * | 2020-11-27 | 2022-04-29 | 山东兴瑞生物科技有限公司 | 一种以tigit和pd-1为靶点的嵌合抗原受体、car-t细胞及其制备方法 |
CA3201767A1 (en) | 2020-12-14 | 2022-06-23 | Thomas M. Schmitt | Compositions and methods for cellular immunotherapy |
WO2022145879A1 (ko) * | 2020-12-28 | 2022-07-07 | 연세대학교 산학협력단 | 면역 관문 저해제의 스크리닝 방법 |
US20240092872A1 (en) | 2021-01-26 | 2024-03-21 | Vir Biotechnology, Inc. | Compositions and methods for treating hepatitis b virus infection |
TW202304965A (zh) | 2021-05-04 | 2023-02-01 | 美商艾吉納斯公司 | 抗tigit抗體、抗cd96抗體及其使用方法 |
WO2023288281A2 (en) | 2021-07-15 | 2023-01-19 | Fred Hutchinson Cancer Center | Chimeric polypeptides |
WO2023010094A2 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法 |
WO2023161943A1 (en) | 2022-02-28 | 2023-08-31 | Nectin Therapeutics Ltd. | Humanized antibodies against nectin-2 and drug conjugates thereof |
WO2023178192A1 (en) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
WO2023230439A1 (en) | 2022-05-23 | 2023-11-30 | Vir Biotechnology, Inc. | Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
JP4169478B2 (ja) | 1998-04-21 | 2008-10-22 | マイクロメット アーゲー | Cd19×cd3特異的ポリペプチドおよびその使用 |
DE69911793T2 (de) | 1998-07-28 | 2004-08-12 | Micromet Ag | Heterominikörper |
EP1481993A1 (en) * | 2003-05-28 | 2004-12-01 | Xerion Pharmaceuticals AG | Modulation of the poliovirus receptor function |
DK1673398T3 (da) | 2003-10-16 | 2011-04-18 | Micromet Ag | Multispecifikke, deimmuniserede CD3-bindere |
WO2005107799A1 (ja) * | 2004-05-06 | 2005-11-17 | Eisai R & D Management Co., Ltd. | 抗Necl-5抗体を有効成分として含む癌治療剤 |
CA2625440C (en) | 2005-10-11 | 2023-06-13 | Micromet Ag | Compositions comprising cross-species-specific antibodies and uses thereof |
CN101541834A (zh) | 2006-10-06 | 2009-09-23 | 武田药品工业株式会社 | 癌症的预防和/或治疗剂 |
JP2010524851A (ja) | 2007-04-03 | 2010-07-22 | マイクロメット アーゲー | 種間特異的結合ドメイン |
EP2252319A2 (en) * | 2008-01-29 | 2010-11-24 | The Brigham and Women's Hospital, Inc. | Methods for modulating a population of myeloid-derived suppressor cells and uses thereof |
MX364200B (es) | 2008-04-09 | 2019-04-16 | Genentech Inc | Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad. |
US10981998B2 (en) | 2008-10-01 | 2021-04-20 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
WO2011159877A2 (en) * | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
WO2012177788A1 (en) * | 2011-06-20 | 2012-12-27 | La Jolla Institute For Allergy And Immunology | Modulators of 4-1bb and immune responses |
HUE038225T2 (hu) | 2011-08-23 | 2018-10-29 | Roche Glycart Ag | Bispecifikus, T-sejtaktiváló antigénkötõ, molekulák |
US20130078250A1 (en) | 2011-08-23 | 2013-03-28 | Oliver Ast | Bispecific t cell activating antigen binding molecules |
MX2015006973A (es) | 2012-12-04 | 2015-09-28 | Oncomed Pharm Inc | Inmunoterapia con agentes de enlace. |
US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
AU2014236769B2 (en) | 2013-03-15 | 2018-09-27 | Amgen Inc. | Heterodimeric bispecific antibodies |
PL3021869T3 (pl) * | 2013-07-16 | 2020-11-16 | F. Hoffmann-La Roche Ag | Sposoby leczenia nowotworu z użyciem antagonistów wiązania osi PD-1 i inhibitorów TIGIT |
AR097648A1 (es) | 2013-09-13 | 2016-04-06 | Amgen Inc | Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide |
WO2015048272A1 (en) | 2013-09-25 | 2015-04-02 | Amgen Inc. | V-c-fc-v-c antibody |
WO2015048312A1 (en) * | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
JOP20200096A1 (ar) * | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2016
- 2016-08-04 JO JOP/2016/0171A patent/JO3620B1/ar active
- 2016-08-05 HU HUE16757165A patent/HUE053763T2/hu unknown
- 2016-08-05 SG SG10202000914VA patent/SG10202000914VA/en unknown
- 2016-08-05 MX MX2018001351A patent/MX2018001351A/es unknown
- 2016-08-05 SI SI201631170T patent/SI3331915T1/sl unknown
- 2016-08-05 CN CN201680045742.3A patent/CN108473572B/zh active Active
- 2016-08-05 CA CA2996015A patent/CA2996015A1/en active Pending
- 2016-08-05 DK DK16757165.2T patent/DK3331915T3/da active
- 2016-08-05 JP JP2018505586A patent/JP7170532B2/ja active Active
- 2016-08-05 UA UAA201802157A patent/UA125375C2/uk unknown
- 2016-08-05 LT LTEP16757165.2T patent/LT3331915T/lt unknown
- 2016-08-05 EP EP16757165.2A patent/EP3331915B1/en active Active
- 2016-08-05 US US15/229,438 patent/US20170037133A1/en not_active Abandoned
- 2016-08-05 TW TW105125042A patent/TWI719041B/zh active
- 2016-08-05 EA EA201890428A patent/EA039307B1/ru unknown
- 2016-08-05 ES ES16757165T patent/ES2861436T3/es active Active
- 2016-08-05 MY MYPI2018700209A patent/MY186582A/en unknown
- 2016-08-05 WO PCT/EP2016/068726 patent/WO2017021526A1/en active Application Filing
- 2016-08-05 AU AU2016301961A patent/AU2016301961B2/en active Active
-
2017
- 2017-12-18 ZA ZA2017/08598A patent/ZA201708598B/en unknown
-
2018
- 2018-01-11 IL IL256874A patent/IL256874B/en unknown
- 2018-01-15 PH PH12018500120A patent/PH12018500120A1/en unknown
- 2018-06-22 HK HK18107990.5A patent/HK1249524A1/zh unknown
- 2018-08-31 US US16/118,994 patent/US20190077869A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
UA125375C2 (uk) | 2022-03-02 |
CA2996015A1 (en) | 2017-02-09 |
SI3331915T1 (sl) | 2021-08-31 |
TW201718002A (zh) | 2017-06-01 |
SG10202000914VA (en) | 2020-03-30 |
EP3331915A1 (en) | 2018-06-13 |
MX2018001351A (es) | 2018-05-22 |
HK1249524A1 (zh) | 2018-11-02 |
CN108473572A (zh) | 2018-08-31 |
JO3620B1 (ar) | 2020-08-27 |
MY186582A (en) | 2021-07-28 |
EP3331915B1 (en) | 2021-02-17 |
JP7170532B2 (ja) | 2022-11-14 |
US20170037133A1 (en) | 2017-02-09 |
AU2016301961B2 (en) | 2021-10-07 |
HUE053763T2 (hu) | 2021-12-28 |
TWI719041B (zh) | 2021-02-21 |
US20190077869A1 (en) | 2019-03-14 |
IL256874A (en) | 2018-03-29 |
ZA201708598B (en) | 2021-04-28 |
DK3331915T3 (da) | 2021-05-03 |
WO2017021526A1 (en) | 2017-02-09 |
CN108473572B (zh) | 2021-10-15 |
EA039307B1 (ru) | 2022-01-12 |
IL256874B (en) | 2022-05-01 |
JP2018531215A (ja) | 2018-10-25 |
LT3331915T (lt) | 2021-06-10 |
PH12018500120A1 (en) | 2018-07-23 |
AU2016301961A1 (en) | 2018-01-18 |
ES2861436T3 (es) | 2021-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201890428A1 (ru) | Ингибиторы контрольных точек иммунного ответа для применения в лечении различных видов рака крови | |
NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
WO2016062722A8 (en) | Combination | |
BR112018008326A2 (pt) | composições e métodos para o tratamento de câncer | |
NZ738008A (en) | Tigit-binding agents and uses thereof | |
MX2018008995A (es) | Combinacion de un agonista de ox40 y un agonista de 4-1bb para tratar el cancer. | |
EA202091964A1 (ru) | КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ | |
CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
EA201990296A1 (ru) | Антитела против siglec-7 для лечения рака | |
CU24498B1 (es) | Anticuerpos de factor xi | |
EA201692285A1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
EA202092000A1 (ru) | Ингибиторы димеризации egfr и их использование | |
EA202090061A1 (ru) | Применение антитела против cd70, argx-110, для лечения острого миелоидного лейкоза | |
WO2018031490A3 (en) | Anti-ox40 binding proteins | |
CY1121806T1 (el) | Ιμιδαζοπυραζινονες ως αναστολεις pde1 | |
MX2018016057A (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
CY1122298T1 (el) | Συνδυασμος αντισωματος anτι-cd19 και αναστολεα τυροσινης κινασης toy bruton και χρησεις του | |
BR112018069976A2 (pt) | anticorpo multiespecífico isolado ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, kit, e, método para tratamento de um indivíduo. | |
BR112019017403A2 (pt) | composições e métodos para o tratamento de câncer | |
CY1121334T1 (el) | Αναστολεας κινασης aurora a | |
MA39909A (fr) | Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer | |
EA201892287A1 (ru) | Фармацевтические комбинации для лечения рака | |
EA201891527A1 (ru) | Композиции и способы обнаружения и лечения рака пищевода | |
MX2019005089A (es) | Anticuerpos anti cumulo de diferenciacion 40 (cd40) en combinacion y metodos de uso. | |
CY1122784T1 (el) | Αλογονωμενες κιναζολιν-τηf-αμινες ως αναστολεις του ρdε1 |